NEW YORK, July 8 — $25 billion. That’s the figure that matters for anyone tracking the business of living longer. By the numbers, the global longevity market hit an estimated $25 billion in 2023, according to Grand View Research.
Investors will note that this valuation captures everything from supplements and diagnostics to drug development targeting the biological mechanisms of aging. The bottom line: as the U.S. Census Bureau projects all baby boomers will be over age 65 by 2030, the addressable market for interventions that extend healthy lifespan is only growing.
The science behind that market is rooted in decades of federal investment. The National Institute on Aging, part of the National Institutes of Health, funds extensive research into how and why we age. The American Federation for Aging Research, founded in 1981, supports early-career scientists entering the field.
What the animal data shows
The oldest thread in longevity research is caloric restriction. Since the 1930s, animal studies have shown that cutting calories can extend lifespan by up to 50% in rodents. That figure has driven decades of follow-up work.
But primate studies tell a more nuanced story. The University of Wisconsin-Madison launched a caloric restriction study in rhesus monkeys in 1987.
Results reported in 2012 showed improved health outcomes for the calorie-restricted animals — but not necessarily increased lifespan. That distinction matters for anyone betting on a simple dietary fix for human longevity. The compound that has generated the most excitement among researchers is rapamycin.
Discovered in 1964 on Easter Island, it extended lifespan in mice by up to 30% in studies published in 2009. That finding turned rapamycin into one of the most-studied molecules in aging research.
Another drug already sitting on pharmacy shelves is metformin. First approved in the U.S. in 1994 as a diabetes treatment, it is now being investigated for its potential to delay aging itself. The TAME trial — Targeting Aging with Metformin — is a multi-center study involving about 3,000 participants aged 65 to 79.
Results from that trial could reshape how regulators and investors think about aging as a treatable condition.
The cellular clock
At the molecular level, much of the research focuses on telomeres — the protective caps on chromosomes that shorten as cells divide. Elizabeth Blackburn and Carol Greider won the 2009 Nobel Prize in Physiology or Medicine for their discovery of telomerase, the enzyme that rebuilds those caps. Their work opened a new avenue for understanding cellular aging.
The maximum human lifespan currently stands at about 122 years, demonstrated by Jeanne Calment, who died in 1997. No one has lived longer since.
Whether interventions like metformin, rapamycin or caloric restriction can push that ceiling higher remains an open question — and the central bet for the $25 billion market. For now, the data is clear on one point: the science of aging has moved from fringe curiosity to a mainstream research priority backed by federal funding, academic institutions and a growing commercial sector. The TAME trial results, when they come, will be the next major data point for the field. Consult your doctor for medical advice.
